Health Care & Life Sciences » Pharmaceuticals | Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals Inc. | Ownership

Companies that own Paratek Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
2,414,775
7.61%
504,796
0%
06/30/2018
The Baupost Group LLC
2,394,498
7.55%
0
0.18%
06/30/2018
Highland Capital Management LP
1,767,000
5.57%
871,800
2.99%
06/30/2018
The Vanguard Group, Inc.
1,285,831
4.05%
159,673
0%
06/30/2018
Armistice Capital LLC
1,132,000
3.57%
552,000
0.88%
06/30/2018
Arbiter Partners Capital Management LLC
776,309
2.45%
682,959
2.8%
06/30/2018
DWS Investment GmbH
553,728
1.75%
74,528
0%
06/30/2018
Renaissance Technologies LLC
539,949
1.7%
-30,900
0.01%
06/30/2018
C WorldWide Asset Management Fondsmæglerselskab A/S
536,128
1.69%
37,875
0.05%
06/30/2018
Norges Bank Investment Management
526,977
1.66%
430,477
0%
12/31/2017

About Paratek Pharmaceuticals

View Profile
Address
75 Park Plaza
Boston Massachusetts 02116
United States
Employees -
Website http://www.paratekpharma.com
Updated 07/08/2019
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and urinary tract infections. The company was founded in February 2001 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.